Interventions Testing Program

Overview

The Interventions Testing Program is the mouse-longevity research project used in Supplements for Longevity & Their Efficacy | Dr. Peter Attia as a comparatively rigorous test of whether candidate interventions change lifespan rather than only pathways or biomarkers.

Current Profile

Within the sources, the program matters less as a catalog of compounds than as an evidence standard. Survival results in mice are used to challenge claims built from mechanism, unusual disease models, observational associations, or subjective response. Peter Attia contrasts negative reported results for NR, resveratrol, and metformin with positive results for rapamycin, canagliflozin, acarbose, and 17-alpha estradiol; the Journal Club also highlights rapamycin benefit when started late in mouse life.

The program is still preclinical. A mouse lifespan result can strengthen or weaken a longevity hypothesis, but it does not establish human benefit, dose, safety, indication, or treatment eligibility.

Key Characteristics

• Tests candidate longevity interventions against survival and healthspan-relevant outcomes in mice.
• Is presented in the source as a stronger filter than mechanism-only reasoning or a single unusual disease model.
• Distinguishes interventions that change mouse lifespan from those that do not in the tested conditions.
• Produces preclinical evidence that still requires human translation.

Evidence

• Design role: Supplements for Longevity & Their Efficacy | Dr. Peter Attia describes the program as the strongest available non-human testing system for candidate lifespan interventions.
• Discriminating results: Supplements for Longevity & Their Efficacy | Dr. Peter Attia reports negative results for NR and resveratrol and positive results for rapamycin, canagliflozin, acarbose, and 17-alpha estradiol.
• Metformin filter: Journal Club With Dr. Peter Attia | Metformin for Longevity & the Power of Belief Effects reports a negative metformin lifespan result and uses it to qualify general geroprotection claims without denying the drug’s established metabolic indication.
• Evidence boundary: Supplements for Longevity & Their Efficacy | Dr. Peter Attia uses those results to reject a direct jump from pathway plausibility to human longevity advice.

Qualifications

This profile is bounded to two podcast sources and is not an independent review of program protocols, every tested dose, sex-specific result, interaction, replication record, healthspan measure, or publication. Mouse survival evidence is informative but cannot by itself establish human clinical efficacy, safety, dose, or indication.

What Changed

• Added metformin’s negative reported result and late-start rapamycin as further examples of the program’s discriminating role.

Relationships

• Mechanism-to-Outcome Evidence Hierarchy - evidence framework the program exemplifies for longevity claims.
• NAD Therapy Evidence Boundary - intervention boundary strengthened by the reported negative NR result.
• Metformin Longevity Evidence Boundary - intervention boundary strengthened by the reported negative metformin result.
• Peter Attia - guest who uses the program as his principal non-human longevity benchmark.
• Huberman Lab - show context in which the program is explained.